$1.02 Billion is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 133 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 105.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | ISHARES TRput | $173,118,000 | +74.0% | 13,865 | +73.3% | 16.96% | +63.7% | |
| AGN | New | ALLERGAN PLC | $53,743,000 | – | 177,100 | +100.0% | 5.26% | – |
| Buy | SPDR SERIES TRUSTput | $50,448,000 | +52.6% | 2,000 | +33.3% | 4.94% | +43.6% | |
| Buy | TEVA PHARMACEUTICAL INDS LTDcall | $38,415,000 | +76.2% | 6,500 | +85.7% | 3.76% | +65.8% | |
| Buy | ISHARES TRput | $27,673,000 | +168.6% | 750 | +150.0% | 2.71% | +152.7% | |
| BIIB | Buy | BIOGEN INC | $24,531,000 | +481.0% | 60,730 | +507.3% | 2.40% | +446.1% |
| MRK | Buy | MERCK & CO INC NEW | $22,772,000 | +5.6% | 400,000 | +6.7% | 2.23% | -0.6% |
| Buy | SELECT SECTOR SPDR TRput | $22,317,000 | +136.8% | 3,000 | +130.8% | 2.19% | +122.8% | |
| CELG | Buy | CELGENE CORP | $18,518,000 | +129.5% | 160,000 | +128.6% | 1.81% | +116.0% |
| New | PERRIGO CO PLCcall | $18,483,000 | – | 1,000 | +100.0% | 1.81% | – | |
| New | BIOMARIN PHARMACEUTICAL INCcall | $13,678,000 | – | 1,000 | +100.0% | 1.34% | – | |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $10,546,000 | +26.3% | 120,000 | +6.7% | 1.03% | +18.9% |
| CXRX | New | CONCORDIA HEALTHCARE CORP | $9,025,000 | – | 100,000 | +100.0% | 0.88% | – |
| VRNT | Buy | VERINT SYS INC | $8,470,000 | +11.8% | 139,434 | +14.0% | 0.83% | +5.2% |
| CHKP | Buy | CHECK POINT SOFTWARE TECH LTord | $7,246,000 | +22.9% | 91,087 | +26.6% | 0.71% | +15.6% |
| BCOMF | New | B COMMUNICATIONS LTD | $6,448,000 | – | 5,977,000 | +100.0% | 0.63% | – |
| PRTA | Buy | PROTHENA CORP PLC | $6,064,000 | +80.4% | 115,133 | +30.6% | 0.59% | +69.7% |
| EWG | Buy | ISHARESmsci germany etf | $5,371,000 | +66.6% | 192,630 | +78.4% | 0.53% | +56.5% |
| GWPH | Buy | GW PHARMACEUTICALS PLCads | $5,344,000 | +67.5% | 43,500 | +24.3% | 0.52% | +57.5% |
| CYNA | New | CYNAPSUS THERAPEUTICS INC | $5,324,000 | – | 316,448 | +100.0% | 0.52% | – |
| TSRO | New | TESARO INC | $5,144,000 | – | 87,500 | +100.0% | 0.50% | – |
| MDCO | Buy | MEDICINES CO | $5,150,000 | +83.8% | 180,000 | +80.0% | 0.50% | +72.6% |
| CATB | New | CATABASIS PHARMACEUTICALS IN | $5,060,000 | – | 446,036 | +100.0% | 0.50% | – |
| ACOR | New | ACORDA THERAPEUTICS INC | $5,000,000 | – | 150,000 | +100.0% | 0.49% | – |
| CPRX | Buy | CATALYST PHARMACEUTICALS INC | $4,956,000 | +4.1% | 1,200,000 | +9.1% | 0.48% | -2.2% |
| RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $4,884,000 | – | 47,700 | +100.0% | 0.48% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $4,565,000 | – | 150,000 | +100.0% | 0.45% | – |
| 3106PS | New | DELPHI AUTOMOTIVE PLC | $4,516,000 | – | 53,070 | +100.0% | 0.44% | – |
| ORBK | Buy | ORBOTECH LTDord | $4,470,000 | +41.8% | 214,922 | +9.3% | 0.44% | +33.5% |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $4,435,000 | – | 37,000 | +100.0% | 0.43% | – |
| KMPH | New | KEMPHARM INC | $4,363,000 | – | 237,500 | +100.0% | 0.43% | – |
| ICPT | Buy | INTERCEPT PHARMACEUTICALS IN | $4,224,000 | -0.1% | 17,500 | +16.7% | 0.41% | -5.9% |
| GNCA | Buy | GENOCEA BIOSCIENCES INC | $4,149,000 | +181.7% | 302,200 | +143.3% | 0.41% | +165.4% |
| BITI | New | BIOTIE THERAPIES OYJsponsored adr | $3,930,000 | – | 196,800 | +100.0% | 0.38% | – |
| FEZ | Buy | SPDR INDEX SHS FDSeuro stoxx 50 | $3,927,000 | +7.6% | 104,920 | +11.6% | 0.38% | +1.3% |
| FOMX | Buy | FOAMIX PHARMACEUTICALS LTD | $3,895,000 | +110.5% | 380,000 | +90.0% | 0.38% | +97.9% |
| NVLS | New | NIVALIS THERAPEUTICS INC | $3,863,000 | – | 255,000 | +100.0% | 0.38% | – |
| RCPT | Buy | RECEPTOS INC | $3,801,000 | +31.7% | 20,000 | +14.3% | 0.37% | +24.0% |
| LIFE | New | ATYR PHARMA INC | $3,696,000 | – | 209,027 | +100.0% | 0.36% | – |
| KRE | New | SPDR SERIES TRUSTs&p regl bkg | $3,536,000 | – | 80,080 | +100.0% | 0.35% | – |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $3,514,000 | – | 150,000 | +100.0% | 0.34% | – |
| MRNS | Buy | MARINUS PHARMACEUTICALS INC | $3,463,000 | +80.4% | 298,533 | +39.8% | 0.34% | +69.5% |
| ARWR | New | ARROWHEAD RESH CORP | $3,396,000 | – | 475,000 | +100.0% | 0.33% | – |
| HALO | New | HALOZYME THERAPEUTICS INC | $3,387,000 | – | 150,000 | +100.0% | 0.33% | – |
| OCUL | New | OCULAR THERAPEUTIX INC | $3,365,000 | – | 160,000 | +100.0% | 0.33% | – |
| PIRS | New | PIERIS PHARMACEUTICALS INC | $3,300,000 | – | 1,200,000 | +100.0% | 0.32% | – |
| RPTP | New | RAPTOR PHARMACEUTICAL CORP | $3,261,000 | – | 206,500 | +100.0% | 0.32% | – |
| TXMD | Buy | THERAPEUTICSMD INC | $3,242,000 | +46.8% | 412,500 | +13.0% | 0.32% | +38.3% |
| MGNX | Buy | MACROGENICS INC | $3,227,000 | +71.5% | 85,000 | +41.7% | 0.32% | +61.2% |
| Buy | TRILLIUM THERAPEUTICS INC | $3,208,000 | +66.9% | 147,000 | +54.7% | 0.31% | +57.0% | |
| XLRN | New | ACCELERON PHARMA INC | $3,164,000 | – | 100,000 | +100.0% | 0.31% | – |
| PAY | Buy | VERIFONE SYS INC | $3,160,000 | +19.9% | 93,055 | +23.2% | 0.31% | +13.1% |
| QURE | Buy | UNIQURE NV | $3,105,000 | +24.6% | 115,000 | +12.3% | 0.30% | +17.4% |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $3,105,000 | – | 125,000 | +100.0% | 0.30% | – |
| MLNX | New | MELLANOX TECHNOLOGIES LTD | $3,054,000 | – | 62,850 | +100.0% | 0.30% | – |
| IMDZ | Buy | IMMUNE DESIGN CORP | $2,891,000 | +5.8% | 140,000 | +8.2% | 0.28% | -0.4% |
| CBYL | New | CARBYLAN THERAPEUTICS INC | $2,860,000 | – | 400,000 | +100.0% | 0.28% | – |
| WIX | New | WIX COM LTD | $2,842,000 | – | 120,305 | +100.0% | 0.28% | – |
| CYTK | New | CYTOKINETICS INC | $2,838,000 | – | 422,250 | +100.0% | 0.28% | – |
| CLCD | New | COLUCID PHARMACEUTICALS INC | $2,824,000 | – | 317,250 | +100.0% | 0.28% | – |
| ISIS | New | ISIS PHARMACEUTICALS INC | $2,762,000 | – | 48,000 | +100.0% | 0.27% | – |
| SCYX | New | SCYNEXIS INC | $2,751,000 | – | 313,000 | +100.0% | 0.27% | – |
| OTIC | Buy | OTONOMY INC | $2,598,000 | +5.0% | 113,000 | +61.4% | 0.25% | -1.6% |
| TRVN | Buy | TREVENA INC | $2,567,000 | +0.5% | 410,000 | +4.6% | 0.25% | -5.6% |
| ELLO | Buy | ELLOMAY CAPITAL LIMITED | $2,518,000 | +33.7% | 246,697 | +11.3% | 0.25% | +26.0% |
| TBRA | New | TOBIRA THERAPEUTICS INC | $2,374,000 | – | 137,622 | +100.0% | 0.23% | – |
| SMMT | Buy | SUMMIT THERAPEUTICS PLCspons ads | $2,280,000 | +5.2% | 205,200 | +17.3% | 0.22% | -1.3% |
| PTN | Buy | PALATIN TECHNOLOGIES INC | $2,261,000 | +113.1% | 2,540,266 | +144.2% | 0.22% | +100.9% |
| WAB | Buy | WABTEC CORP | $2,108,000 | +3.2% | 22,365 | +4.0% | 0.21% | -3.3% |
| ALDX | Buy | ALDEYRA THERAPEUTICS INC | $2,056,000 | +72.2% | 265,000 | +130.4% | 0.20% | +62.1% |
| CHTR | New | CHARTER COMMUNICATIONS INC Dcl a new | $1,724,000 | – | 10,065 | +100.0% | 0.17% | – |
| New | APTOSE BIOSCIENCES INC | $1,415,000 | – | 221,096 | +100.0% | 0.14% | – | |
| NICE | New | NICE SYS LTDsponsored adr | $1,161,000 | – | 18,250 | +100.0% | 0.11% | – |
| CARA | New | CARA THERAPEUTICS INC | $567,000 | – | 46,700 | +100.0% | 0.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.